EXHIBIT 99.1

                   Court Sets Date in Diomed Patent Litigation

ANDOVER, MA, November 6, 2006, --- Diomed Holdings, Inc. (AMEX: DIO - News), a
leading developer and marketer of minimally invasive medical technologies,
including its patented EndoVenous Laser Treatment (EVLT(R)) for varicose veins,
today announced that the United States Federal District Court for the District
of Massachusetts has set a hearing date on December 8, 2006 to establish a trial
date for its `777 patent litigation against its primary competitors
AngioDynamics and Vascular Solutions, Inc.

In January 2004, Diomed commenced legal action in the against AngioDynamics,
seeking injunctive relief and damages for infringement of Diomed's pioneering
United States Patent Number 6,398,777 which covers the endovascular laser
treatment of varicose veins. Diomed acquired exclusive rights to the patent from
the five inventors of the procedure in September 2003. Diomed initiated similar
actions against Vascular Solutions and two other competitors later in 2004.

Earlier this year U.S. District Judge Nathaniel M. Gorton ruled that Diomed's
U.S. Patent No. 6,398,777 is both valid and enforceable. In granting Diomed's
motion for summary judgment, the court rejected defenses advanced by defendants
AngioDynamics and Vascular Solutions that Diomed's patent was invalid and
unenforceable. The court denied separate motions by each of the parties for
summary judgment on the issue of infringement by the defendants, in effect
ruling that Diomed is entitled to proceed to trial on its claims for an
injunction and damages against the defendants.

"We are very pleased to have a firm date to schedule the trial," stated James A.
Wylie, Jr., President and Chief Executive Officer of Diomed Holdings, Inc. "We
are very much looking forward to the successful conclusion to this important
litigation."




About Diomed

Diomed develops and commercializes minimal and micro-invasive medical procedures
that use its proprietary laser technologies and disposable products. Diomed's
EVLT(R) laser vein ablation procedure is used in varicose vein treatments.
Diomed also provides photodynamic therapy (PDT) for use in cancer treatments,
and dental and general surgical applications. The EVLT(R) procedure and the
Company's related products were cleared by the United States FDA in January of
2002. Along with lasers and single-use procedure kits for its EVLT(R) laser vein
treatment, the Company provides its customers with state of the art physician
training and practice development support. Additional information is available
on the Company's website: www.evlt.com.

EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.

Safe Harbor statements under the Private Securities Litigation Reform Act of
1995: Statements in this news release looking forward in time involve risks and
uncertainties, including the risks associated with trends in the products
markets, reliance on third party distributors in various countries outside the
United States, reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These statements relate to
our future plans, objectives, expectations and intentions. These statements may
be identified by the use of words such as "may," "will," "should," "potential,"
"expects," "anticipates," "intends," "plans," "believes" and similar
expressions. These statements are based on our current beliefs, expectations and
assumptions and are subject to a number of risks and uncertainties. Our actual
results could differ materially from those discussed in these statements. Our
Annual Report on Form SEC 10-KSB/A (the "Annual Report") contains a discussion
of certain of the risks and uncertainties that affect our business. We refer you
to the "Risk Factors" on pages 23 through 38 of the Annual Report for a
discussion of certain risks, including those relating to our business as a
medical device company without a significant operating record and with operating
losses, our risks relating to our commercialization of our current and future
products and applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct any of its
forward-looking statements.

For more information contact:

Christopher J. Geberth, VP Finance          Carney Noensie
Diomed Holdings, Inc.                       Burns McClellan, Investor Relations
Phone:   866-4DIOMED                        Phone:  212-213-0006
email: cgeberth@diomedinc.com               email :  cduntsch@burnsmc.com